|
|
|
|
| LEADER |
01140nam a2200349Ia 4500 |
| 001 |
10.1111-biom.13495 |
| 008 |
220427s2021 CNT 000 0 und d |
| 020 |
|
|
|a 0006341X (ISSN)
|
| 245 |
1 |
0 |
|a Rejoinder: Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes
|
| 260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1111/biom.13495
|
| 650 |
0 |
4 |
|a biology
|
| 650 |
0 |
4 |
|a COVID-19
|
| 650 |
0 |
4 |
|a COVID-19
|
| 650 |
0 |
4 |
|a Data Interpretation, Statistical
|
| 650 |
0 |
4 |
|a disease control
|
| 650 |
0 |
4 |
|a drug
|
| 650 |
0 |
4 |
|a drug therapy
|
| 650 |
0 |
4 |
|a health risk
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a randomized controlled trial (topic)
|
| 650 |
0 |
4 |
|a Randomized Controlled Trials as Topic
|
| 650 |
0 |
4 |
|a SARS-CoV-2
|
| 650 |
0 |
4 |
|a statistical analysis
|
| 700 |
1 |
|
|a Benkeser, D.
|e author
|
| 700 |
1 |
|
|a Díaz, I.
|e author
|
| 700 |
1 |
|
|a Luedtke, A.
|e author
|
| 700 |
1 |
|
|a Rosenblum, M.
|e author
|
| 700 |
1 |
|
|a Scharfstein, D.
|e author
|
| 700 |
1 |
|
|a Segal, J.
|e author
|
| 773 |
|
|
|t Biometrics
|
